Treatment of von Willebrand's disease.
Recent unraveling of the molecular and cellular biology of vWF and clearer knowledge of the pathophysiology of vWD have dramatically advanced our understanding of this group of disorders. Nonetheless, safe, effective, therapeutic management remains a formidable challenge for the clinician caring for these patients.
Logan
L J
LJ
Department of Medicine (Hematology), University of Southern California School of Medicine, Los Angeles.
D016913:Blood Component Transfusion; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D005169:Factor VIII / Q000096:biosynthesis / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D008297:Male; D013514:Surgical Procedures, Operative; D014842:von Willebrand Diseases / Q000145:classification / Q000150:complications / Q000235:genetics / Q000628:therapy*; D014841:von Willebrand Factor / Q000096:biosynthesis / Q000378:metabolism / Q000627:therapeutic use
D014841:von Willebrand Factor; D005169:Factor VIII; D013006:Growth Hormone; D003894:Deamino Arginine Vasopressin